Drugs by condition
Drugs approved for tardive dyskinesia
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
6
Still marketed, NDA or BLA
Drug classes
1
Novel drugs
2
New molecular entities and new biologics
In development
2
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for tardive dyskinesia.
- Ingrezza Sprinkle (Valbenazine Tosylate) · Neurocrine OrphanApr 30, 2024
- Austedo Xr (Deutetrabenazine) · Teva OrphanFeb 17, 2023
- Gimoti (Metoclopramide Hydrochloride) · Qol Medcl Jun 19, 2020
- Ingrezza (Valbenazine Tosylate) · Neurocrine NovelBreakthrough therapyPriority reviewOrphanApr 11, 2017
- Austedo (Deutetrabenazine) · Teva Branded Pharm NovelOrphanApr 3, 2017
All approved drugs for tardive dyskinesia, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 33 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Class not listed in FDA's data (6)
- Ingrezza Valbenazine Tosylate · Neurocrine · 2017
- Austedo Deutetrabenazine · Teva Branded Pharm · 2017
- Ingrezza Sprinkle Valbenazine Tosylate · Neurocrine · 2024
- Austedo Xr Deutetrabenazine · Teva · 2023
- Gimoti Metoclopramide Hydrochloride · Qol Medcl · 2020
- Reglan Metoclopramide Hydrochloride · Ani Pharms · 1980
Drugs in development for tardive dyskinesia
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- LY03015LPM3770164 sustained releasePhase 21 trial
Luye Pharma Group Ltd. · Tardive Dyskinesia (TD)
- NBI-1065890Phase 21 trial
Neurocrine Biosciences · Tardive Dyskinesia
More on tardive dyskinesia: recruiting trials · published research
Related in neurology: Alzheimer's disease · Parkinson's disease · Multiple sclerosis · Epilepsy and seizures · Migraine · ALS (amyotrophic lateral sclerosis) · Myasthenia gravis · Spinal muscular atrophy · Duchenne muscular dystrophy · Huntington's disease chorea
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.